{"id":"58844e0f-2aae-5797-b7ba-ff81af2024c0","stable_key":"availability:acute-illness-low-circulating-selenium:1","predicate":"can_lower","statement":"Acute inflammation can lower circulating selenium through multiple illness-related processes.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"source_reported: Human observational context and mechanistic interpretation; source-derived unverified synthesis.","direction":"negative","is_public":true,"mechanism_event_id":"06dadb2f-c78b-589e-9c17-dc764edd6573","mechanism_event_label":"Acute inflammation can lower circulating selenium through multiple illness-related processes.","subject":{"id":"1fc8af78-46e8-5579-a95b-cc5f8318b18a","slug":"acute-inflammation","display_name":"Acute inflammation","entity_type_key":"cellular_process"},"object":{"id":"037a44ae-8573-572b-a4a7-237fe5ccad11","slug":"circulating-selenium-pool","display_name":"Circulating selenium pool","entity_type_key":"chemical_species"},"evidence_count":1,"mechanism_event":{"id":"06dadb2f-c78b-589e-9c17-dc764edd6573","stable_key":"availability:acute-illness-low-circulating-selenium:1","event_type":"availability_dependent_change","label":"Acute inflammation can lower circulating selenium through multiple illness-related processes.","description":"Acute inflammation or severe illness changes hepatic priorities, protein distribution, losses, or intake. Inflammatory and acute-illness measurement context, including observational associations with illness severity.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"1fc8af78-46e8-5579-a95b-cc5f8318b18a","slug":"acute-inflammation","display_name":"Acute inflammation","entity_type_key":"cellular_process"},"role":"condition_input","stoichiometry":null,"state_label":"Acute inflammation or severe illness changes hepatic priorities, protein distribution, losses, or intake.","sequence_order":0,"notes":""},{"entity":{"id":"037a44ae-8573-572b-a4a7-237fe5ccad11","slug":"circulating-selenium-pool","display_name":"Circulating selenium pool","entity_type_key":"chemical_species"},"role":"affected_component","stoichiometry":null,"state_label":"Acute inflammation or severe illness changes hepatic priorities, protein distribution, losses, or intake.","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"Acute inflammation or severe illness changes hepatic priorities, protein distribution, losses, or intake.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_scope","value_text":"Inflammatory and acute-illness measurement context, including observational associations with illness severity.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Inflammation and true deficiency can coexist. This is neither proof of adequate nutrition nor proof that supplementation benefits outcomes. Deliberate nutritional immunity remains a hypothesis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"e127aa1a-1277-5e14-ba46-2dd989064469","evidence_kind":"source_passage","locator":"lines 627-643","start_line":627,"end_line":643,"excerpt":"6.2 Acute-phase confounding\n\nInflammation can lower circulating selenium and SELENOP. Cytokine signaling, hepatic reprioritization, albumin changes, redistribution, illness severity, renal losses, and nutritional intake can all contribute.\n\nacute inflammation / severe illness\n        ↓\nhepatic and systemic protein redistribution\n        ↓\nSELENOP and circulating selenium can fall\n\nTherefore:\n\nA low selenium concentration during acute illness does not, by itself, prove dietary deficiency.\n\nIt also does not prove that nutritional deficiency is absent; inflammation and true deficiency can coexist.\n\nAssociations between low selenium and poor ICU outcomes are vulnerable to reverse causation and confounding by illness severity.","model_system":"Supplied reference; verify the primary study and experimental context.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"c788c19c-884c-5233-92b1-0bd063d87741","stable_key":"deficiency","title":"Selenium deficiency: a mechanism-first reference","document_type":"user_supplied_reference","citation_label":"Supplied selenium deficiency reference","file_path":"X:\\metabolic-ledger\\source_material\\selenium-deficiency-reference.md","sha256":"a3f14bc3fa24c595dda830664523090a7b5bfa76e9dcf517f42f62212ceb767e","revision_id":"f8f97804-c1fb-56df-9c06-c02e36e2a5b8","review_status":"unverified_draft","notes":"Preserved verbatim. Reported study types are source labels, not independent verification."}}],"relations":[],"conflicts":[],"corrections":[{"id":"59a0cc94-e785-5c3a-a23f-fa3630f0d23d","title":"Acute-phase selenium changes and a null sepsis trial do not prove pathogen feeding","kind":"qualification","status":"qualified","why":"IL-6 suppression supports biomarker confounding, not adaptive withholding. SISPCT did not establish why treatment failed or pathogen-mediated harm.","resolution":"Measurements need illness context; retain possible coexisting deficiency and label nutritional immunity unproven.","created_at":"2026-09-17 07:19:34","record_type":"qualification","display_label":"Source qualification","record_url":"/corrections/59a0cc94-e785-5c3a-a23f-fa3630f0d23d","literature_review":{"revision_id":"80984e03-5f0f-5877-8094-afef7637444e","start_line":1668,"end_line":1674,"papers":[{"paper_key":"martitz-2015","title":"Gene-specific regulation of hepatic selenoprotein expression by interleukin-6","url":"https://pubs.rsc.org/en/content/articlelanding/2015/mt/c5mt00211g","doi":"10.1039/C5MT00211G","year":2015,"model":"Human hepatocyte cultures","summary":"IL-6 lowers SELENOP expression/secretion; adaptive purpose untested."},{"paper_key":"bloos-2016","title":"Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial","url":"https://pubmed.ncbi.nlm.nih.gov/27428731/","doi":"10.1001/jamainternmed.2016.2514","year":2016,"model":"SISPCT randomized human trial; 1089 analyzed","summary":"No demonstrated mortality benefit for tested regimen; no established pathogen-feeding explanation."}]},"sides":[{"conflict_id":"59a0cc94-e785-5c3a-a23f-fa3630f0d23d","ordinal":0,"label":"Original preserved statement","revision_id":"fbed30e0-1c0d-5b83-8a1f-2867fbe8a5b5","start_line":384,"end_line":390,"quote":"**(a) Plasma selenium measured during acute illness is uninterpretable.** You're reading the acute phase response, not nutritional status. Every observational \"low selenium predicts ICU mortality\" finding is contaminated by reverse causation — sicker patients have more IL-6.\n\n**(b) The inversion:** bacteria need selenium. *C. difficile* runs Stickland fermentation on **selenium-dependent proline and glycine reductases**. E. coli needs Sec for formate dehydrogenase. **What if hyposelenemia is nutritional immunity — selenium withholding, exactly analogous to hepcidin sequestering iron and calprotectin sequestering zinc?**\n\nIf that's right, then **large-dose IV selenium in sepsis is feeding the pathogen while overriding a host defense**, which is precisely the pattern seen with iron supplementation in malaria-endemic populations.\n\n**And the large ICU selenium trials (SISPCT and others) are null.** That is the predicted result. Nobody has run the obvious experiment: does selenium supplementation increase bacterial selenoprotein expression in vivo, and does the effect differ between Se-dependent and Se-independent organisms? **This is cheap, and I think it's the single most likely place a real finding is sitting unclaimed.**","claim_id":null,"source_key":"immune","source_title":"Selenium in immune cells","claim_ids":[]},{"conflict_id":"59a0cc94-e785-5c3a-a23f-fa3630f0d23d","ordinal":1,"label":"Original preserved statement","revision_id":"f8f97804-c1fb-56df-9c06-c02e36e2a5b8","start_line":629,"end_line":651,"quote":"Inflammation can lower circulating selenium and SELENOP. Cytokine signaling, hepatic reprioritization, albumin changes, redistribution, illness severity, renal losses, and nutritional intake can all contribute.\n\nacute inflammation / severe illness\n        ↓\nhepatic and systemic protein redistribution\n        ↓\nSELENOP and circulating selenium can fall\n\nTherefore:\n\nA low selenium concentration during acute illness does not, by itself, prove dietary deficiency.\n\nIt also does not prove that nutritional deficiency is absent; inflammation and true deficiency can coexist.\n\nAssociations between low selenium and poor ICU outcomes are vulnerable to reverse causation and confounding by illness severity.\n\nNull supplementation trials do not prove that every observational association is reverse causation.\n\nBest practice: interpret selenium alongside the clinical context and, when relevant, inflammatory markers such as CRP plus other nutritional markers such as albumin. Do not use a single acutely ill plasma value as a complete nutritional diagnosis.\n\nNutritional-immunity hypothesis\n\nSome microorganisms use selenium-dependent enzymes, making host–pathogen selenium competition biologically plausible. The idea that acute hyposelenemia functions as deliberate “nutritional immunity,” analogous to iron sequestration, is an interesting hypothesis rather than an established clinical mechanism. It should not be used to infer that selenium supplementation “feeds the pathogen” without direct evidence in the relevant infection.","claim_id":null,"source_key":"deficiency","source_title":"Selenium deficiency: a mechanism-first reference","claim_ids":[]},{"conflict_id":"59a0cc94-e785-5c3a-a23f-fa3630f0d23d","ordinal":2,"label":"Literature correction and experimental limits","revision_id":"80984e03-5f0f-5877-8094-afef7637444e","start_line":1668,"end_line":1674,"quote":"## Acute-phase selenium changes and a null sepsis trial do not prove pathogen feeding\n\nIL-6 suppression supports biomarker confounding, not adaptive withholding. SISPCT did not establish why treatment failed or pathogen-mediated harm.\n\nMeasurements need illness context; retain possible coexisting deficiency and label nutritional immunity unproven.\nPrimary reference: [Gene-specific regulation of hepatic selenoprotein expression by interleukin-6](https://pubs.rsc.org/en/content/articlelanding/2015/mt/c5mt00211g)\nPrimary reference: [Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial](https://pubmed.ncbi.nlm.nih.gov/27428731/)","claim_id":null,"source_key":"selenium-research-2026-09-17","source_title":"Selenium: literature corrections and mechanism additions","claim_ids":[]}]}],"research":null}